Ginkgo Bioworks (NYSE: DNA) reported Q2 EPS of ($0.11), $0.03 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $56 million versus the consensus estimate of $43.14 million.

GUIDANCE:

Ginkgo Bioworks sees Q3 2024 revenue of $170-190 million, versus the consensus of $179.5 million.

Ginkgo continues to expect Cell Engineering services revenue of $120-140 million in 2024
Ginkgo continues to expect Biosecurity revenue of at least $50 million in 2024

For earnings history and earnings-related data on Ginkgo Bioworks (DNA) click here.